U.S.Patent and Trademark Office (PTO) has ruled in the favour of Natco Pharma’s marketing partner Mylan, with regard to patent claims pertaining to multiple sclerosis drug Copaxone.
Tags : U.S.PATENT AND TRADEMARK OFFICE NATCO PHARMA PATENT CLAIMS
Share :